New FY2018 Revised Forecast by Segments January 31, 2019

Consumer Foods	New FY2018 Revised Forecast (Jan. 31, 2019) *2	FY2018 Revised Forecast (Nov. 7, 2018) *2	Difference	FY2017 Results *2, *4	YoY Change	New 4Q-FY18 Revised Forecast *2	4Q-FY17 Results *2, *4	YoY Change	Reasons for New FY2018 Revised Forecast
Sales	859.9	871.3	▲ 11.4	848.8	11.0	212.6	207.9	4.6	
Japan Food Products	380.4	384.5	▲ 4.1	384.1	▲ 3.7	93.7	91.5	2.1	
Seasonings & processed foods	195.5	195.9	▲ 0.4	190.2	5.2	49.7	45.7	4.0	
Frozen foods (Japan)	97.8	101.4	▲ 3.6			23.6		▲ 0.4	[Japan Food Products]
Coffee products	87.1	87.1	0.0			19.6		▲ 2.1	Seasonings & processed foods: Downward revision of business profit based primarily on results up through 3Q for
International Food Products	479.5	486.8	▲ 7.3		14.7	118.8			restaurant and industrial use.
Seasonings & processed foods	298.3	304.3	▲ 6.0	293.1	5.1	75.3		2.9	
Frozen foods (Overseas)	116.4	117.1	▲ 0.7			29.5			Frozen foods (Japan): Downward revision of both sales and business profit based on results up through 3Q.
Umami seasonings for processed food mfrs.	64.7	65.3	▲ 0.6			13.9			Coffee and votes. Device vond revision of by since a profit become an recultor up through 20
Business profit*1	68.6	77.1	<u>▲ 8.5</u>	80.3		9.7	7 12.3		Coffee products: Downward revision of business profit based on results up through 3Q.
Japan Food Products Seasonings & processed foods	29.2	32.7	▲ 3.5 ▲ 1.0			3.5	5.1 6.1	▲ 1.6 0.0	[International Food Products]
Frozen foods (Japan)			<u> </u>				1 2		
Coffee products			<u> </u>				1.2	▲ 1.0	business profit due to impairment loss on the trademark rights of Promasidor Holdings Limited.
Shared companywide expenses	▲ 12.5	▲ 12.5	0.0			▲ 3.8	3		baomoco prometado to impainmente loco em ano tradomante riginto en riversacion riversarigo Emintosa.
International Food Products	39.4	44.4	▲ 5.0			6.2	7.2	▲ 0.9	Frozen foods (Overseas): Downward revision of sales and upward revision of business profit based on results up
Seasonings & processed foods			<u>▲</u> 5.1			0.2		▲ 1.3	through 3Q.
Frozen foods (Overseas)	1.3	1.0	0.3	2.3	▲ 1.0	0.7	7 ▲ 0.4		
Umami seasonings for processed food mfrs.			▲ 0.1					▲ 0.5	
Shared companywide expenses	▲ 15.1	▲ 15.1	0.0		0.0	▲ 4.6	6 ▲ 4.4		
Amino Science	Revised Forecast (Jan. 31, 2019) *2	Revised Forecast (Nov. 7, 2018) *2	Difference	FY2017 Results *2, *4	YoY Change	Revised Forecast *2	4Q-FY17 Results *2, *4	YoY Change	Reasons for New FY2018 Revised Forecast
Sales	260.3	257.3	3.0	238.5		81.8		14.8	
Life Support*3	118.4	118.2	0.2			35.8			
Animal nutrition	83.5	83.5	0.0	87.0		27.8	3 22.8		
Specialty chemicals			0.2		3.5		7.2	0.5	
Other	1110	120.4	0.0			45.0	0.5		
Healthcare*3	141.9	139.1	2.8			45.9			
Amino acids Amino acids for			3.0	79.2	19.5		26.6	8.0	
pharmaceuticals and foods				36.5			10.5		
Pharmaceutical custom manufacturing				43.0			16.0		[Life Support]
Other			▲ 0.2		2.5		9.6	1.5	Specialty chemicals: Upward revision of both sales and business profit based on results up through 3Q.
Business profit*1	20.1	21.1	▲ 1.0	17.4		5.0	5.2	▲ 0.2	[Healthcare]
Life Support*3	9.0	8.4	0.6	8.0	0.9	1.3	3 1.7		Amino acids: Upward revision of sales based on results up through 3Q.
Animal nutrition	2.0	2.0	0.0	3.0	▲ 1.0	0.7	7 1.1	▲ 0.4	Amino acids. Opward revision of sales based on results up through sq.
Specialty chemicals			0.8	9.4			2.1	0.0	Other: Downward revision of both sales and business profit based on results up through 3Q.
Other			▲ 0.3	▲ 0.7	▲ 0.0		▲ 0.4		Cariori Devirtual a revieteri et sear carec aria suchi ecc premi sacca en recanic ap a meagir eq.
Shared companywide expenses	▲ 3.5	▲ 3.5	0.0			▲ 1.2		▲ 0.1	
Healthcare*3	11.1	12.7	▲ 1.6			3.6	3.5	0.1	
Amino acids			▲ 0.2	9.0	3.5		4.0	0.5	
Amino acids for pharmaceuticals and foods									
Pharmaceutical custom manufacturing				1.0	A 10			1 2 -	
Other Shared company wide expanses	A 4 0	1 10	▲ 1.4		A 1.0	A 4 C	0.7	▲ 0.5	
Shared companywide expenses	▲ 4.3	▲ 4.3	0.0	▲ 3.8	▲ 0.4	▲ 1.3	3 ▲ 1.2	▲0.0	

New 4Q-FY18

Revised

Forecast

Other	New FY2018 Revised Forecast (Jan. 31, 2019) *2	FY2018 Revised Forecast (Nov. 7, 2018) *2	Difference	FY2017 Results *2, *4	YoY Change	
Sales	26.6	26.6	0.0	27.3	▲ 0.7	
Business profit*1	▲ 2.5	▲ 2.5	0.0	▲ 2.1	▲ 0.3	
Shared companywide expenses	▲ 2.6	▲ 2.6	0.0	▲ 2.2	▲ 0.3	

Consolidated	New FY2018 Revised Forecast (Jan. 31, 2019) *2	FY2018 Revised Forecast (Nov. 7, 2018) *2	Difference	FY2017 Results *2, *4	YoY Change
Sales	1,146.8	1,155.2	▲ 8.4	1,114.7	32.0
Business profit*1	86.2	95.7	▲ 9.5	95.6	▲ 9.4

 5.8
 7.5
 ▲ 1.6

 ▲ 2.8
 ▲ 0.0

 ▲ 0.8
 ▲ 0.5
 ▲ 0.3

 New 4Q-FY18
 Revised
 Forecast
 *2, *4
 *2
 YoY Change

 *2, *4
 *1.8

 11.9
 14.7
 ▲ 2.8

4Q-FY17 Results

YoY Change

Reasons for New FY2018 Revised Forecast

Reasons for New FY2018 Revised Forecast

(¥ Billion)

Nondisclosure

(Italic) Approximation

^{*1} A profit indicator defined by Ajinomoto for administrative purposes

Sales - Cost of sales - Selling expenses, Research & development expenses and General & administrative expenses + Share of profit of associates and joint ventures

^{*2} From FY2018, the logistics business has been reclassified as a discontinued operation. Accordingly, profit from discontinued operation is presented separately from the profit from continuing operations.

Sales, and business profit in the above table are amounts related to continuing operations only. Amounts shown for FY2017, have also been adjusted to reflect this change.

*3 Segment changes (reclassification of results for prior years):

Materials of healthcare products, which had been included in Specialty Chemicals under Life Support, was changed to Other under Healthcare from FY2018, and this is reflected in all figures in this category.

^{*4} In the previous fiscal year, the Company finalized a provisional accounting treatment related to business combinations and jointly controlled company.

The figures for the FY2017, reflect the finalization of the provisional accounting treatment.

[•]Forward-looking statements, such as business performance forecasts, made in these materials are based on management's estimates, assumptions and projections at the time of publication and do not represent a commitment from Ajinomoto Co., Inc. that they will be achieved. A number of factors could cause actual results to differ materially from expectations.

Unaudited figures are included in these materials for reference.

[•]Amounts presented in these materials are rounded down.